Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Phase 3positivetulisokibartPositive
AI Analysis
Summary
Merck announced positive topline results from the Phase 3 ATLAS-UC induction-only study showing that tulisokibart met primary and key secondary endpoints in patients with moderately to severely active ulcerative colitis.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Met primary and key secondary endpoints in Phase 3 ATLAS-UC induction-only study
Importance:8/10
Sentiment:
0.85
Phase 3ulcerative colitispositive dataATLAS-UCinduction-only
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on June 22, 2026 11:07 PM